Chris P Conlon FRCP
Professor of Infectious Diseases
- Head of NDM Experimental Medicine
- Member of congregation
- Group Head / PI
- Consultant Physician and Unit Director
I am responsible for a mixture of clinical, teaching, research and administrative duties, including covering the 18 bed Infectious Diseases Unit at the Churchill Hospital. I collaborate with colleagues in HIV research and am currently on the trial steering committee of the RIVER study; a proof of principle trial of HDAC inhibitors and HIV vaccine use in an attempt to ‘cure’ HIV. I also run the TB service in Oxford and collaborate with Professor Derrick Crook and others using whole genome sequencing to improve diagnoses. I also have oversight of the Tropical Medicine Group and was recently invited to lecture at The First Beijing International Conference on Precision Medicine and Cancer Treatment Forum with a talk entitled "Medical Education in the 21st Century"
I am a Fellow and Tutor in Clinical Medicine at Oriel College, Oxford and regularly teach Oxford medical undergraduates in lectures and seminars, and at the bedside. In addition, I am a Principal Examiner in Medicine in Oxford and Chair of the Royal College of Physicians Joint Specialty Committee for Infectious Diseases.
I was appointed Interim Head of Department for the Nuffield Department of Medicine in May 2016. I have also been the Head NDM Experimental Medicine since 2014.
Self-maintaining CD103+ cancer-specific T cells are highly energetic with rapid cytotoxic and effector responses
Abd Hamid M. et al, (2019), Cancer Immunology Research, canimm.0554.2019 - canimm.0554.2019
A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer
Li X. et al, (2019), Frontiers in Oncology, 9
Enriched HLA-E and CD94/NKG2a interaction limits anti-tumor CD8(+) tumor-infiltrating T lymphocyte responses
Abd Hamid MHB. et al, (2019), EUROPEAN JOURNAL OF IMMUNOLOGY, 49, 1252 - 1253
Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8+ tumor-infiltrating T lymphocyte responses.
Abd Hamid M. et al, (2019), Cancer Immunol Res
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
Gossez M. et al, (2019), AIDS, 33, 185 - 197